Journal article
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
Abstract
Purpose: To test the activity of the cyclin dependent kinase (cdk) inhibitor flavopiridol in malignant melanoma, a disease with frequent abnormalities of the cyclin dependent kinase system. Patients and methods: Patients had histologically proven, unidimensionally measurable malignant melanoma, incurable by standard therapy. Prior adjuvant immunotherapy was allowed, but patients were otherwise untreated for advanced disease. Flavopiridol was …
Authors
Burdette-Radoux S; Tozer RG; Lohmann RC; Quirt I; Ernst DS; Walsh W; Wainman N; Colevas AD; Eisenhauer EA
Journal
Investigational New Drugs, Vol. 22, No. 3, pp. 315–322
Publisher
Springer Nature
Publication Date
August 2004
DOI
10.1023/b:drug.0000026258.02846.1c
ISSN
0167-6997